SCHEMBL1790366

SCHEMBL1790366

Cn1ncc(Cl)c1CNC(=O)c1ccc2c(c1)CCN(C1=CC=C1)CC2

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.40
P2RX7 Q99572 2/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
OPRM1 P35372 2/20 0.36
OPRK1 P41145 1/20 0.36
OPRL1 P41146 1/20 0.36
HPGD P15428 1/20 0.35
WNT1 P04628 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.34
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789970 0.84 ROCK2 (0.49) SMN1; SMN2HDAC6MAPTKMT2AROCK2
SCHEMBL1787647 0.82 KMT2A (0.47) LMNAGSK3BHDAC6KMT2AROCK2
SCHEMBL1789905 0.82 ROCK2 (0.48) RAB9ALMNASMN1; SMN2WNT1GSK3B
SCHEMBL1790364 0.81 HRH3 (0.48) RAB9AHDAC6
SCHEMBL1790327 0.79 GAA (0.48) LMNASMN1; SMN2ALDH1A1MAPTROCK2
SCHEMBL1787760 0.79 MAPT (0.50) RAB9ALMNASMN1; SMN2OPRK1MAPT
SCHEMBL1787247 0.79 KMT2A (0.37) OPRM1OPRK1HDAC6MAPTKMT2A
SCHEMBL1792607 0.79 ROCK2 (0.48) RAB9ALMNASMN1; SMN2HPGDALDH1A1
SCHEMBL1791556 0.79 ITK (0.44) GSK3BHDAC6KMT2AROCK2ROCK1
SCHEMBL1787706 0.78 HDAC6 (0.43) RAB9ASMN1; SMN2OPRK1HDAC6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 RAB9A 2688/4885P2RX7 969/4885LMNA 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.